This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Novo Nordisk targets Indian drugmaker Dr Reddy's over formulation, trademark claims

By Freny Patel ( March 26, 2026, 05:08 GMT | Insight) -- The semaglutide legal battle in India has entered a new phase, with Novo Nordisk taking on Dr. Reddy’s Laboratories over formulation patents and trademark concerns, just after the expiry of the patent protection for the blockbuster drug.Novo Nordisk filed fresh litigation in the Delhi High Court this week against Dr. Reddy’s Laboratories over its plans to launch a generic version of semaglutide, just as patent protection for the blockbuster drug expired on March 20, 2026....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections